SCHEMBL7180798

SCHEMBL7180798

Cc1cc(C)c(C(=O)Pc2c(OCc3ccccc3)cc(OCc3ccccc3)cc2OCc2ccccc2)c(C)c1C.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
PTGER1 P34995 1/20 0.40
FFAR1 O14842 2/20 0.40
MAPT P10636 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAOB P27338 4/20 0.39
PTPN1 P18031 1/20 0.39
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181193 0.88 FFAR4 (0.45) FFAR4MEN1KMT2ARXRARXRB
SCHEMBL7189484 0.87 RXRA (0.47) FFAR4MEN1KMT2ARXRARXRB
SCHEMBL7187077 0.87 MAOB (0.44) FFAR4MEN1KMT2ARXRARXRB
SCHEMBL7190536 0.85 MRGPRX4 (0.45) FFAR4MEN1KMT2ARXRARXRB
Lithium SCHEMBL7187088 0.84 MAOB (0.44) FFAR4MEN1KMT2ARXRARXRB
SCHEMBL7185643 0.84 MAOB (0.46) FFAR4FFAR1L3MBTL1CYP2C19SMN1; SMN2
SCHEMBL7180555 0.82 MRGPRX4 (0.44) FFAR4MEN1KMT2ARXRARXRB
SCHEMBL7182561 0.82 MAOB (0.46) FFAR4MEN1KMT2AFFAR1L3MBTL1
SCHEMBL7184403 0.81 MRGPRX4 (0.49) MEN1KMT2ARXRAPTGER1FFAR1
SCHEMBL7179980 0.81 RXRA (0.46) MEN1KMT2ARXRATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FFAR4 1611/4885MEN1 2312/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FFAR4 1526/4885MEN1 2263/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.